Treatment with atezolizumab or durvalumab, a monoclonal antibody directed against programmed cell death ligand 1 (PDL1), resulted in improved overall survival of patients with extensive stage small cell lung cancer (ES-SCLC) when combined with first-line chemotherapy (Horn et al., 2018, Paz-Ares et al., 2019). Here, CD274 is linked to small cell lung carcinoma.